Fusogenic membrane glycoproteins (FMG) are potent therapeutic transgenes with potential utility in the gene therapy of gliomas. FMG expression constructs caused massive syncytia formation followed by cytotoxic cell death in glioma cell lines, and antitumor activity has been shown in glioma xenografts. FMG-induced fusion in glioma cells can involve heterologous cell lines including normal astrocytes and fibroblasts, therefore making targeting important. Here we report on the use of matrix metalloproteinase (MMP) cleavable linkers to target cytotoxicity of FMGs against gliomas. Expression constructs were made expressing the hyperfusogenic version of the Gibbon Ape Leukemia Virus envelope glycoprotein (GALV) linked to a blocking ligand (the C-terminal extracellular domain of CD40 ligand) via either an MMP cleavable linker (GALV M40), a factor Xa protease cleavable linker (GALV X40), or a noncleavable linker (GALV N40). Unmodified GALV expressing constructs were used as positive controls. The glioma cell lines U87, U118, and U251 previously characterized by zymography and MMP-2 activity assay as high, medium, and low MMP expressors, respectively; normal human astrocytes and the MMP-poor cell line TE671 were transfected with the GALV, GALV N40, GALV X40, and GALV M40 constructs. In contrast to unmodified GALV constructs, transfection with GALV X40 and GALV N40 constructs blocked fusion and cytotoxic cell death. Fusion occurred, however, after transfection with constructs containing MMP cleavable linkers to an extent dependent on MMP expression in the specific cell line. Use of the broad-spectrum MMP inhibitors, 1,10-phenanthroline and N-hydroxy-piperazine-carboxamide completely abolished the ability of MMP constructs to induce fusion. In cell mixing experiments, mixing of MMP-poor cell lines transfected with GALV M40 constructs with the MMP overexpressing untransfected U87 glioma cells led to partial restoration of fusion. Use of U87 supernatant did result in a similar effect. Establishment of stable tranfectants expressing the membrane-type MMPs, MT-1 MMP and MT-2 MMP did restore fusion in the MMP-poor cell line TE671 after transfection with GALV M40, thus indicating that both membrane-type MMPs and soluble MMPs activate the MMP cleavable constructs. In addition, the GALV M40 construct retained its cytotoxic activity against U87 cells in vivo, although less effectively as compared to unmodified GALV. Our data indicate that GALV-induced cytotoxicity in glioma cell lines can be blocked by display of the CD40 ligand. Incorporation of an MMP cleavable linker can selectively restore cytotoxicity in MMP expressing glioma cell lines both in vitro and in vivo, while sparing normal human astrocytes. Given the high frequency of MMP overexpression in gliomas, this represents a promising targeting strategy. Gene Therapy (2003) 10, 725-732.
Introduction
Fusogenic membrane glycoproteins (FMG) have recently emerged as a novel class of potent therapeutic transgenes with potential utility in the gene therapy of different malignancies, including gliomas. We have shown that transfection of glioma cell lines with expression constructs encoding for two different FMGs, the measles virus F and H glycoproteins, and a hyperfusogenic version of the Gibbon ape leukemia virus (GALV) glycoprotein caused cell-cell fusion and massive syncytia formation followed by cytotoxic cell death. The cytotoxic effect was at all time points superior to the HSV-tk ganciclovir system and the bystander effect achieved was at least 1 log higher and estimated at 40:1.
Transfection of the tumorigenic cell line U87 with F and H or GALV completely abolished its tumorigenicity, while use of viral vectors coding for FMGs led to tumor regression and prolongation of survival in established U87 xenografts. 1 Similarly, antitumor activity was observed in a variety of other tumor cell lines including Mel 624 (melanoma), HT 1080 (fibrosarcoma), 2 Hep3B (hepatoma), 3 and against an HT1080 xenograft model. 4 The FMG receptors CD46 (recognizes the H glycoprotein) 5 and Pit-1 (recognizes GALV) 6 are ubiquitously expressed in primate cells. As a result, FMG-induced fusion of tumor cells can spread in heterologous cell lines, including normal cells. In the case of gliomas, we showed that F and H or GALV-transfected U87 cells can fuse and kill untransfected normal human astrocytes and fibroblasts. 1 Therefore, the need to target FMG cytotoxicity in order to improve their therapeutic ratio and enhance their clinical applicability becomes obvious.
The goal of this study was to determine if the cytotoxicity of the GALV fusogenic membrane glycoprotein in gliomas can be targeted by display of a blocking ligand through protease cleavable linkers. The hyperfusogenic form of GALV that has been explored as a therapeutic transgene has a truncation of the cytoplasmic R peptide and is expressed as a trimer on the cell surface. 7 Thus, as a blocking ligand, we chose to display, at the N-terminus of GALV, a trimeric polypeptide, the C-terminal domain of the CD40 ligand. Trimeric polypeptides, when displayed at the N-terminus of the retroviral glycoprotein, have been shown to create significant steric impedance to viral attachment and entry. 8, 9 A protease cleavage signal between GALV and CD40 ligand ( Figure 1 ) could allow selective cleavage of CD40 ligand blocking domain and activation of GALV in the protease-rich tumor environment, but not in normal tissues. We chose to explore the overexpression of matrix metalloproteinases (MMPs) in gliomas in order to achieve targeted activation of GALV.
The MMPs belong to a family of structurally related endopeptidases that mediate the degradation of different protein components of the extracellular matrix and basement membrane, and are believed to play an important role in tumor invasion and angiogenesis. 10 Human glioma cell lines have been shown to express a variety of MMPs in vitro. Similarly, immunohistochemical localization studies in surgical specimens have confirmed that MMPs are overexpressed in high-grade gliomas, such as glioblastoma multiforme and anaplastic astrocytomas. [11] [12] [13] [14] In contrast, there is no MMP expression in normal brain tissue. MMPs most frequently expressed in malignant gliomas include gelatinase-A, gelatinase-B (MMP-2 and MMP-9, respectively), and the membrane-type MMPs, MT-1, and MT-2 MMP. 9, 12, 14 Overexpression of MMP in gliomas makes MMPs a valid approach in targeting gene transfer in gliomas.
Materials and methods

Cell lines
The glioma cell lines U87, U251, U118, and rhabdomyosarcoma cell line TE671 were obtained from ATCC (Manassa, VA, USA) and maintained in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S). Normal human astrocytes were obtained from Clonetics (Walkersville, MD, USA) and maintained in AGM growth medium (Clonetics, Walkersville, MD, USA). TE671 cells, stably transfected with MT-1 MMP or MT-2MMP expression constructs, were maintained in DMEM/10%FBS/1%P/S containing 1 mg/ml geneticin (G418, Life Technologies, Rockville, MD, USA).
Expression constructs
The chimeric expression constructs are shown diagrammatically in Figure 1c . As seen in Figure 1c , the linkers were the MMP cleavable linker GGPLGLWAGG, the noncleavable linker GGGGS, and the factor Xa protease cleavable linker IEGR. The GGPLGLWAGG linker is cleaved by a broad spectrum of MMPs including gelatinases (MMP-2 and MMP-9) and MTI-MMP. 15, 16 The factor Xa protease cleaves IEGR after the arginine residue. 17 A NotI-Cla fragment containing the linker GALV cDNA was PCR amplified from the GALV envelope cDNA. To obtain GALV M40, GALV N40, and GALV X40, PCR primers GALV G2M.N (5 0 GCA AAT CTG CGG CCG CAG GGG GAC CTT TGG GAC TTT GGG CAG GCG GTA GTC TGC AAA ATA AGA ACC CCC AC 3 0 ) GALVG4S.N (5 0 GCA AAT CTG CGG CCG CAG GTG GAG GCG GTT CAA GTC TGC AAA ATA AGA ACC CCC AC 3 0 ), and GALVX.N (5 0 GCA AAT CTG GGG CCG CAA TCG AGG GAA GGA GTC TGC AAA ATA AGA ACC CCC AC 3 0 ), respectively, were used with primer Cla GALV.b (5 0 ATC GAT ATC GAT TCA TCA ACA TGC ACT TAT CCT ATC, ATT G 3 0 ). The PCR fragments were digested with the restriction enzymes NotI and Cla, and subcloned into the NotI-Cla digested CD40L.G4S.A construct. 8 The constructs were verified and checked by diagnostic digest and DNA sequencing.
MMP-2 activity assay
Cells (2 Â 10 5 ) were seeded in 35 mm dishes and supernatants were collected after 48 h of incubation at 371C and frozen at -801C until the time of MMP-2 measurement. The cells were trypsinized and counted at the time of supernatant collection in order to normalize for differential growth rates between cell lines. Total MMP-2 levels were measured with the MMP-2 activity assay system (Amersham Pharmacia Biotech, Piscataway, NJ, USA) according to the manufacturer's instructions. In addition, the MMP activity of the glioma cell lines we 
Assessment of MMP linker cleavage
The ability of MMP expressing cell lines to cleave the specific MMP linker used in our constructs was analyzed as previously described. 19 Briefly, MMP-rich U87 and U118 and MMP-poor TE671 cells at 75% confluency were exposed to 20 mM synthetic fluorogenic MMP substrate DNP-Pro-Leu-Gly-Leu-Trp-Ala-D-Arg-NH 2 (Calbiochem, San Diego, CA, USA) using serum-free conditions at 371C for 5.5 h in triplicate. Media were collected from each sample and separated by reverse-phase HPLC using a C18 column. Fragments were visualized and quantified by monitoring column effluence at 220 nm. The synthetically constructed cleavage product Leu-TrpAla-D-Arg-NH 2 (Mayo Protein Core Facility, Rochester, MN, USA) was used as the positive control. The data were presented as a ratio of the peak area of the cleaved product, divided by the peak area of the intact substrate.
Calcium phosphate transfection
Cells were seeded at a density of 4 Â 10 4 per 16 mm dish (24-well plate), 2 Â 10 5 per 35 mm dish (six-well plate), or 10 6 per 100 mm dish 24 h prior to transfection. Cells were transfected with the Calcium Phosphate Profection Mammalian Transfection System kit (Promega, Madison, WI, USA), according to the manufacturer's instructions. In all, 1, 5, or 20 mg DNA per dish was used for the 16, 35, or 100 mm dishes, respectively.
Quantitation of fusion
Extent of fusion directly correlates with FMG-induced cytotoxicity.
1,2 The percentage of maximum fusion was determined as follows: at 48 h, cells were fixed with 0.5% glutaraldehyde. The average area occupied by the nuclear cluster per syncytium was estimated using a 4 Â 4 grid under 20 Â phase in X5 different fields per well in duplicate wells. Cells were then stained with 2% crystal violet and the number of syncytia per 2 mm 2 of a grid was counted under 4 Â magnification in duplicate wells. The average nuclear area per syncytium multiplied by the average number of syncytia per square was calculated (syncytial index) and expressed as a percentage of the control plasmid. All experiments were repeated at least twice.
Western immunoblotting
Expression of MT-1 MMP and MT-2 MMP in stable TE671 transfectants. TE671 cells (1 Â 10 6 ) stably transfected with MT-1 MMP or MT-2 MMP expression constructs were lysed with 0.5 ml of lysis buffer (50 mM sodiumpyrophosphate, 50 mM NaF, 50 mM NaCl, 5 mM EDTA, 5 mM EGTA, 100 mM Na 3 VO 4 , 10 mM Hepes pH 7.4, 0.1% Triton X-100, 0.5 mM PMSF, and 10 mg/ml leupeptin). Cell lysates were frozen at À201C. Protein in each lysate was quantified with the Biorad protein assay kit according to the manufacturer's instructions. A measure of 40 mg of each lysate in 1 Â Laemmli buffer was boiled for 5 min and then electrophoresed on an 8% SDS-PAGE gel and electrotransferred onto a nitrocellulose membrane (Hybond ECL, Amersham Life Sciences, Amersham, UK). Membranes were incubated overnight in 5% BSA and 5% milk at 41C. MT-1 MMP and MT-2 MMP expression was detected by chemiluminescence on membranes incubated with 10 mg/ml biotinylated MT-1 MMP and MT-2 MMP mouse monoclonal, respectively (Calbiochem, La Jolla, CA, USA), in 1% BSA, 1% milk for 1 h at room temperature, washed four times for 15 min with PBS/0.003% Tween-20, incubated with 1mg/ml peroxidase-conjugated streptavidin in 1% BSA, 1% milk for 1 h at room temperature, and washed four times for 15 min, 1 Â overnight.
Inhibitor studies
Cells were transfected in 35 mm dishes as described above. After washing, the MMP inhibitor was added. We used two different broad-spectrum MMP inhibitors: (a) 1,10 phenanthroline (Aldrich, Milwaukee, WI, USA); concentrations 0 and 12.5 mM; and (b) N-hydroxy 5,5-dimethyl-piperazine-2-carboxamide; concentrations 0, 10, 100 mM (Calbiochem, La Jolla, CA, USA). In order to exclude nonspecific protease inhibition, we used as control, the serine protease inhibitor, soybean trypsin inhibitor (Roche, Nutley, NJ, USA) in the known inhibitory concentrations of 0, 1, and 1 mg/ml. Cells were fixed with 0.5% glutaraldehyde 48 h after transfection, and counting of syncytia was performed as described above.
Cell mixing experiments
Cells were transfected in 10 cm dishes as described. After 4 h, cells were washed and trypsinized. Transfected and untransfected cells were mixed at equal numbers (2 Â 10 5 per cell line/per well) and seeded in six-well plates. After 48 h, cells were fixed with 0.5% glutaraldehyde and quantitation of fusion was performed as described above.
Effect of U87 supernatant on GALV M40-induced infusion in cell lines expressing low MMP levels U87 supernatant was added to TE671 cells, transfected with GALV M40, 4 h post-transfection. Cells were fixed with 0.5% glutaraldehyde at 24 and 48 h.
Establishment of TE671 transfectants overexpressing membrane-type MMPs
The membrane-type metalloproteinase MT-1 MMP and MT-2 MMP encoding constructs were a kind gift from Dr Kevin Hotary and have been published previously. 10 Transfections of TE671 cells with the MT-1 MMP or MT-2 MMP constructs were performed as described above. Selection was started 24 h later with 1 mg/ml G418 (Life Technologies, Rockville, MD, USA).
Effect of transfection with protease cleavable constructs on tumor growth in vivo U87 cells were transfected with (a) GALV, (b) GALV M40, and (c) GALV N40 as described above. After 4 h and prior to any fusion being observed, cells were washed, trypsinized, and injected subcutaneously in the flanks of Balb C/nude mice. In all, 5 Â 10 6 cells/animal were used, 9-10 animals per group. U87 untransfected cells were used as negative control (six animals). Tumor volume was measured three times a week until the animals were euthanized. The experiment was terminated on day 32 when several of the animals in the two control groups (inoculated with untransfected U87 cells or 
Statistical analysis
The Kruskall-Wallis test was used to compare tumor growth among the different animal groups. T-test was used to compare syncytial indexes in the cell mixing experiments.
Results
Characterization of MMP activity
The glioma cell lines used in our experiments and normal human astrocytes have been previously characterized by zymography regarding MMP expression.
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U87 has the highest MMP expression followed by U118 and U251 while normal human astrocytes do not express MMPs. MMP-2 activity assay of the tumor cell lines employed in our experiments confirmed these results ( Figure 2 ). Furthermore, we tested the ability of our cell lines to cleave the specific MMP linker incorporated in our constructs by testing their ability to cleave a fluorogenic substrate that is identical to the linker and detect cleavage products by HPLC ( Figure 3 ). As Figure 3 illustrates, the MMP-rich cell lines U87 and U118 easily cleave the substrate while minimal cleavage is observed with the MMP-poor cell line TE671.
Targeting of GALV-induced fusion with MMP cleavable GALV constructs
In order to target GALV cytotoxicity against gliomas, we displayed a blocking ligand, the C-terminus of the CD40L at the N-terminus of GALV tethered via protease cleavable or noncleavable linkers. Transfections of glioma cell lines expressing variable levels of MMPs, normal human astrocytes, and the MMP-poor nonglioma cell line TE671 were then performed (Figures 4 and 5) . Transfections with either the noncleavable or the protease Xa cleavable linker GALV constructs either completely eliminated or significantly diminished GALV-induced fusion as compared to the unmodified GALV envelope. In contrast, use of an MMP cleavable linker restored fusion to an extent directly dependent on MMP expression (and linker cleavage) by the specific cell line. Normal human astrocytes were completely protected by using this targeting approach.
Inhibitor studies
In order to prove the specificity of our targeting approach, we used two different broad-spectrum MMP inhibitors: 1,10-phenanthroline and N-hydroxy-5,5-dimethyl-piperazine-2-carboxamide. They both completely abolished fusion induced by the MMP cleavable linker containing GALV construct (Figures 6a and b) . In contrast, a nonspecific inhibitor, soybean trypsin inhibitor (serine protease inhibitor), did not affect MMPinduced fusion (data not shown). 
Cell mixing experiments
Restoration of fusion in MT-1 MMP and MT-2 MMP stable TE671 transfectants demonstrated that membrane-type MMPs do play a role in the activation of the GALV M40 construct. We also wanted to investigate if soluble MMPs can activate the construct by cleaving the blocking ligand after expression of the chimeric protein in the cell surface. Therefore, we mixed MMP-poor TE671 cells, transfected with the GALV construct containing the MMP cleavable linker, with MMP overexpressing U87 cells. Partial restoration of GALV M40 fusion was seen in the presence of U87 cells (Figure 8a ). The same effect was reproduced by using U87 supernatant (Figure 8b ). After transfection of TE671 cells with GALV M40, addition of U87 cell supernatant significantly increased fusion at 48 h (P¼0.03).
Transfection with GALV M40 prior to tumor cell inoculation suppresses glioblastoma tumor growth in vivo
In order to examine if the antitumor effect of MMP cleavable constructs observed in vitro persists in an in vivo tumor environment, we inoculated U87 cells transfected with (a) unmodified GALV, (b) GALV M40, and (c) GALV N40 subcutaneously in Balb C/nude mice. U87 untransfected cells were used as a second negative control. Transfection with GALV M40 significantly suppressed tumor growth as compared to GALV N40 transfection (P¼0.005) and untransfected U87 cells (P¼0.02) (Figure 9 ). In contrast, there was no difference between the two negative controls (GALV N40 and untransfected U87 cells) (P¼0.5).
The results show that the in vivo tumor environment does not negate the antitumor effect observed in vitro with the MMP cleavable constructs. Nevertheless, it does decrease its potency since transfection with unmodified GALV constructs prior to tumor cell inoculation completely eliminated tumor growth (P¼0.001).
Discussion
FMG including the measles virus F and H proteins and GALV have recently emerged as a novel potent class of therapeutic transgenes. [1] [2] [3] [4] The ubiquitous expression of their cellular receptors (CD46 and Pit-1, respectively) in primate cells, however, can lead to the fusion of normal neighboring tissues 1 and limit their applicability, especially if systemic transgene administration is Gliomas were chosen as a therapeutic target because of the high frequency of MMP overexpression [11] [12] [13] [14] 18 and the prior demonstration of the therapeutic efficacy of FMGs including GALV in this setting. 1 We have tested our constructs in three different glioma cell lines, which we selected on the basis of their MMP expression levels (high, medium, and low MMP expressors). Our findings support the potential utility and applicability of this 20 In addition, in vivo MMP-targeted retroviral vectors displaying CD40 ligand at the N-terminus of their amphotropic envelope showed a strong selectivity for MMP-rich HT1080 xenografts. 9 Fielding et al 21 have shown that infectivity of retroviral vectors incorporating GALV envelopes on which EGF was displayed was restricted on EGF receptor-positive cells, but not on EGF receptor-negative cells, and could be restored by protease cleavage of the displayed domain.
Our animal experiments showed that cleavage of the blocking ligand can also be accomplished in vivo, thus maintaining its antitumor effect against the MMP-rich glioma cell line U87. However, the potency of the antitumor effect was somewhat diminished as compared to unmodified GALV (Figure 9 ). Although factors such as different transfection efficacy may be responsible for this result, a more sensitive MMP cleavage signal, as identified by retroviral display libraries, could possibly further enhance potency while maintaining its specificity 22 (CJ Buchholz, personal communication). We are in the process of constructing adenoviral vectors encoding the targeted constructs in order to prove the therapeutic efficacy of this approach in glioma xenografts in vivo. MMP overexpression in gliomas in contrast to very low or undetectable MMP expression in the surrounding normal brain makes our approach a very appealing targeting strategy, if intratumoral administration of the therapeutic fusogenic transgene in the CNS is contemplated. Nevertheless, for systemic administration of the retargeted constructs, additional transcriptional control of transgene expression, that is, by adding a tumor specific promoter, may become necessary in order to further decrease the chance of peripheral activation of the fusogenic transgene and ensure tumorspecific transgene expression.
In summary, our results indicate that MMP cleavable linkers can target the cytotoxicity of the GALV fusogenic glycoprotein when used as therapeutic transgene in gliomas. The same approach could also be applicable to a broad spectrum of solid tumors, such as colon cancer, pancreatic cancer, melanoma, and ovarian cancer [23] [24] [25] [26] [27] characterized by MMP overexpression. p=0.005 Figure 9 Growth curves of U87 xenografts after transfection of U87 cells with GALV M40, GALV, and GALV N40 prior to inoculation. Untransfected U87 cells were used as a second negative control.
Transfection of U87 cells with GALV M40 prior to tumor cell inoculation significantly inhibited tumor growth as compared to untransfected U87 cells (P¼0.02) and U87 cells transfected with GALV N40 (noncleavable linker) constructs (P¼0.005). There was no difference in growth observed for U87 untransfected cells and U87 cells transfected with GALV N40 (P¼0.5).
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